Quick Dispatch:
Your tirzepatide cvot Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis ships.
Need Help?
Questions about tirzepatide cvot Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis in your area.
SURPASS-CVOT: Tirzepatide better than dulagluti
27.73
Frontiers
26.82
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
29.45
New SURPASS-CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound
22.63
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
23.33
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
20.78
Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention
20.07
